Thanks INNOVIT - Italian Innovation and Culture Hub for the enriching two weeks in the San Francisco bay area. Now back to work in Rome as we every day closer to product launch.
Chi siamo
MEDICUD is an Italian medical device startup, involved in the wound healing sector. MEDICUD has developed DRYUM, an incisional negative pressure wound therapy system combining gold standard and patient comfort. It is the only ultraportable mechanic system delivering constant negative pressure during the whole treatment. DRYUM is a cost effective system that aims to be the new standard of care in incisional surgery, reducing dramatic complications such as surgical site infection and dehiscence. DRYUM has a reduced ecological impact thanks to the extensive use of bio-sourced polymers and the absence of embedded electronics. DRYUM is now in the clinical phase with in human trials.
- Settore
- Strumenti medicali
- Dimensioni dell’azienda
- 2-10 dipendenti
- Sede principale
- Roma
- Tipo
- Società privata non quotata
- Data di fondazione
- 2020
- Settori di competenza
- medical devices, wound healing e medtech
Località
-
Principale
Ottieni indicazioni
Roma, 00100, IT
Dipendenti presso MEDICUD
Aggiornamenti
-
Let's start another week on tour. Our founders Antonio Nunzio D'angelo & Andrea Cazzulani are in San Francisco as a part of the INNOVIT - Italian Innovation and Culture Hub health cohort. Showcasing our technology to west coast partners. If you are in the bay area and want to know more of how Medicud has the new standard of care in post operative care send us a PM. #medicaldevice #bayarea #medtech #seed
-
-
Our founders are at Viva Technology showcasing MEDICUD and The brand new DRYUM device version. Come say hi bu stand c11
-
-
🎇Today is the day! 🏥Finally we will test our DRYUM device in a relevant environment. 📐Usability testing and user training are happening right now. 👩⚕️👨⚕️Next step? In human clinical validation #medicaldevice #woundhealing #trial
-
-
Let's close this week with an important announcement 🚀 We have been selected among the best 30 European health-tech startups in the seed phase. 📈 Next months will be dedicated to improve our business model and being ready for next stage of investment. 🔍 We are one step closer in bringing DRYUM to the market 🏥
🔈Congratulations to the 30 start-ups that have been selected for the Catapult 2023-24 semifinals! 🏥#LifeSciences: Celex Oncology Innovations Ltd Celtic Biotech Ltd G.ST Antivirals Integra Therapeutics Lactocore Group Orgavalue Pan Cancer T POLYGON Therapeutics Tezted R-nuucell 📱#Healthtech: Acorai Bearcover Digistain® Dymium Exhalation Technology Ltd FEYENALLY Fideliomed Five Lives SpeakTX iYoni App Look HealSee Lumetry Diagnostics GmbH MEDICUD nen neuroClues Plio Surgical Saphenus Medical Technology TRAK Verdify XTremedy Medical 🤝They will now receive high-quality training from experienced entrepreneurs, investors, and experts in the field. This mentorship is tailored to each start-up's individual needs to strengthen and optimise their business plans and pitches. 🏆The top nine start-ups (three from life sciences and six from healthtech) will be selected and invited to pitch during the finals at Bits & Pretzels HealthTech in Munich on 5-6 June 2024. 👉Find out more: https://loom.ly/-DNbqT8